RT Journal Article
SR Electronic
T1 Therapeutic Application of Chloroquine in Clinical Trials for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.22.20040964
DO 10.1101/2020.03.22.20040964
A1 Divya RSJB Rana
A1 Santosh Dulal
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.22.20040964.abstract
AB The novel corona virus disease -2019 (COVID-19) pandemic has caused a massive global public health havoc. Recent clinical trials carried out in China has found a promising therapeutic application of chloroquine and hydroxychloroquine for COVID-19. This study meticulously evaluated the various dosages of chloroquine and hydroxychloroquine utilized in clinical trials registered in Chinese and US clinical trial registries for the treatment of pneumonia caused by SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialreview articleFunding StatementNot applicableAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo extra data required.